IP Library Granted Patent US 8,461,384
Granted Patent B2
US 8,461,384 · App. 12/481,993 · Granted Jun 11, 2013

Preparation of amides from an acid and amine for intermediates in the synthesis of morphinans

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,384
App. No.
12/481,993
Granted
Jun 11, 2013
Kind
B2
Abstract

The present invention is directed to processes for the synthesis of morphinans. In particular, a process for coupling a carboxylic acid compound with an amine compound to form an amide product that can then be isolated or the crude amide product can be cyclized to form a 3,4-dihydroisoquinoline. In one embodiment, the carboxylic acid contains a phenol moiety protected with a labile protecting group. The protected phenol reduces reaction times, simplifies work-up of the product, and reduces the amount of cyclizing agent, POCl 3 that is necessary to form the 3,4-dihydroisoquinoline.

Claims (68)

1. A process for the preparation of an amide corresponding to Formula 502, the process comprising treating an acid corresponding to Formula 301 with an amine corresponding to Formula 400 under anhydrous conditions and at a temperature of from about 25° C. to about 100° C. to form the amide corresponding to Formula 502:

wherein

R 1 and R 7 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 111 ;

R 2 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 211 ;

R 3 is hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 311;

R 4 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 411 ;

R 5 and R 6 are independently hydrogen, hydrocarbyl, substituted hydrocarbyl, or —OR 511 ;

R 12 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 121 ;

R 13 is hydrogen, hydrocarbyl, substituted hydrocarbyl, halo, or —OR 511 ;

R 111 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

R 211 is hydrogen, hydrocarbyl, —C(O)R 212 , —C(O)NHR 213 , or SO 2 R 214 ;

R 212 , R 213 , and R 214 are independently hydrocarbyl or substituted hydrocarbyl;

R 311 is hydrogen, hydrocarbyl, —C(O)R 312 , —C(O)NHR 313 , or —SO 2 R 314 :

R 312 is alkyl or aryl, provided, R 312 is other than methyl or phenyl;

R 313 is hydrocarbyl or substituted hydrocarbyl;

R 314 is alkyl or aryl, provided, R 314 is other than methyl;

R 411 is hydrogen, hydrocarbyl, —C(O)R 412 , —C(O)NHR 413 , or —SO 2 R 414 ;

R 412 is alkyl or aryl, provided, R 412 is other than methyl or phenyl;

R 413 and R 414 are independently hydrocarbyl or substituted hydrocarbyl;

R 511 is hydrogen, hydrocarbyl, or substituted hydrocarbyl; and

R 121 is hydrogen, hydrocarbyl, or substituted hydrocarbyl;

wherein at least one of R 2 , R 3 , or R 4 is —OC(O)R 212 , —OC(O)NHR 213 , —OSO 2 R 214 , —OC(O)R 312 , —OC(O)NHR 313 , —OSO 2 R 314 , —OC(O)R 412 , —OC(O)NHR 413 , or —OSO 2 R 414 .

2. The process of claim 1 , wherein:

R 2 is —OR 211 ;

R 211 is hydrogen, alkyl, —C(O)R 212 , —C(O)NHR 213 , or —SO 2 R 214 ; and

R 212 , R 213 , and R 214 are independently hydrocarbyl or substituted hydrocarbyl.

3. The process of claim 1 , wherein:

R 3 is —OR 311 ;

R 311 is hydrogen, alkyl, —C(O)R 312 , —C(O)NHR 313 , or —SO 2 R 314 ;

R 312 is alkyl or aryl, provided, R 312 is other than methyl or phenyl;

R 313 is hydrocarbyl or substituted hydrocarbyl; and

R 314 is alkyl or aryl, provided, R 314 is other than methyl.

4. The process of claim 1 , wherein:

R 4 is —OR 411 ;

R 411 is hydrogen, alkyl, —C(O)R 412 , —C(O)NHR 413 , or —SO 2 R 414 ;

R 412 is alkyl or aryl, provided, R 412 is other than methyl or phenyl; and

R 413 and R 414 are independently alkyl or aryl.

5. The process of claim 1 , wherein R 12 is alkyl, allyl, benzyl, or halo.

6. The process of claim 1 , wherein R 3 is methoxy, R 4 is hydroxyl, —OC(O)CH 2 CH 3 , or —OSO 2 CH 3 , R 6 is methoxy, and R 1 , R 2 , R 5 , R 7 , R 12 , and R 13 are hydrogen.

7. The process of claim 1 , wherein:

R 2 is —OR 211 ;

R 211 is hydrogen, alkyl, —C(O)R 212 , —C(O)NHR 213 , or —SO 2 R 214 ;

R 212 , R 213 , and R 214 are independently hydrocarbyl or substituted hydrocarbyl;

R 3 is —OR 311 ;

R 311 is hydrogen, alkyl, —C(O)R 312 , —C(O)NHR 313 , or —SO 2 R 314 ;

R 312 is alkyl or aryl, provided, R 312 is other than methyl or phenyl;

R 313 is hydrocarbyl or substituted hydrocarbyl;

R 314 is alkyl or aryl, provided, R 314 is other than methyl;

R 4 is —OR 411 ,

R 411 is hydrogen, alkyl, —C(O)R 412 , —C(O)NHR 413 , or —SO 2 R 414 ;

R 412 is alkyl or aryl, provided, R 412 is other than methyl or phenyl; and

R 413 and R 414 are independently alkyl or aryl.

8. The process of claim 7 , wherein R 12 is alkyl, allyl, benzyl, or halo.

9. The process of claim 7 , wherein R 212 , R 213 , R 214 , R 313 , R 413 , and R 414 are methyl.

10. The process of claim 7 , wherein R 12 is alkyl, allyl, benzyl, or halo; and R 212 , R 213 , R 214 , R 313 , R 413 , and R 414 are methyl.

11. The process of claim 1 , wherein anhydrous conditions are obtained by removal of water from the reaction mixture by distillation.

12. The process of claim 1 , wherein anhydrous conditions are obtained by addition of a water scavenging agent to the reaction mixture.

13. The process of claim 1 , wherein the temperature of the reaction mixture is from about 40° C. to about 90° C.

14. A compound corresponding to Formula 502:

wherein

R 1 and R 7 are hydrogen,

R 2 is hydrogen;

R 3 is methoxy;

R 4 is —OC(O)CH 3 or—OSO 2 CH 3 ;

R 5 is hydrogen;

R 6 is methoxy;

R 12 is hydrogen; and

R 13 is hydrogen.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: SPECGX LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2009
From: GROTE, CHRISTOPHER W.; WANG, PETER X.; MOSER, FRANK W.; CANTRELL, GARY L.
To: MALLINCKRODT INC.
Reel/Frame 022816/0357 →